KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts. Show more

Location: 55 Cambridge Parkway, Cambridge, MA, 02142, United States | Website: https://www.kalvista.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

725.3M

52 Wk Range

$7.30 - $16.32

Previous Close

$15.51

Open

$14.88

Volume

2,086,126

Day Range

$13.85 - $15.00

Enterprise Value

314.6M

Cash

253.2M

Avg Qtr Burn

-31.91M

Insider Ownership

1.47%

Institutional Own.

-

Qtr Updated

01/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.